GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Other Current Liabilities

Kintara Therapeutics (STU:3DMA) Other Current Liabilities : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Other Current Liabilities?

Kintara Therapeutics's other current liabilities for the quarter that ended in Mar. 2024 was €0.00 Mil.


Kintara Therapeutics Other Current Liabilities Historical Data

The historical data trend for Kintara Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Other Current Liabilities Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kintara Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kintara Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.


Kintara Therapeutics Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (STU:3DMA) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines